FRI-009-Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements

MLA

Alexandra Rousseau, et al. “FRI-009-Bezafibrate Add-on Therapy in High-Risk Primary Biliary Cholangitis Is Associated with Prolonged Predicted Survival Even in Patients with Incomplete Biochemical Improvements.” Journal of Hepatology, vol. 70, Apr. 2019, pp. e386–87. EBSCOhost, https://doi.org/10.1016/s0618-8278(19)30759-5.

APA

Alexandra Rousseau, Christophe Corpechot, Olivier Chazouillères, Sara Lemoinne, Karima Ben Belkacem, Gaouar Farid, & Raoul Poupon. (2019). FRI-009-Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements. Journal of Hepatology, 70, e386–e387. https://doi.org/10.1016/s0618-8278(19)30759-5

Chicago

Alexandra Rousseau, Christophe Corpechot, Olivier Chazouillères, Sara Lemoinne, Karima Ben Belkacem, Gaouar Farid, and Raoul Poupon. 2019. “FRI-009-Bezafibrate Add-on Therapy in High-Risk Primary Biliary Cholangitis Is Associated with Prolonged Predicted Survival Even in Patients with Incomplete Biochemical Improvements.” Journal of Hepatology 70 (April): e386–87. doi:10.1016/s0618-8278(19)30759-5.